Kevin R. Aroom

Kevin R. Aroom

Auto-generated profile, based on publicly available information

Kevin R. Aroom

Department of Pediatric Surgery, University of Texas Medical School at Houston, Houston, Texas

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2016 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
MGMitchell George
Mitchell George
KAKevin R. Aroom
Kevin R. Aroom
HHHarvey G. Hawes
Harvey G. Hawes
BGBrijesh S. Gill
Brijesh S. Gill
JLJoseph Love
Joseph Love

2 April 2013 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
AOA. B. Olsen
A. B. Olsen
RHR. A. Hetz
R. A. Hetz
HXH. Xue
H. Xue
KAK. R. Aroom
K. R. Aroom
DBD. Bhattarai
D. Bhattarai
KUKaren Uray
Karen Uray

5 March 2017 in Stem Cells
Verified
Journal Article
Closed access
PDF file
MDMiguel F. Diaz
Miguel F. Diaz
AVAbishek B. Vaidya
Abishek B. Vaidya
SESiobahn M. Evans
Siobahn M. Evans
HLHyun J. Lee
Hyun J. Lee
BABenjamin M. Aertker
Benjamin M. Aertker
Pamela WenzelPamela Wenzel
Pamela Wenzel

4 November 2013 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
SBSupinder S. Bedi
Supinder S. Bedi
RHRobert Hetz
Robert Hetz
CTChelsea Thomas
Chelsea Thomas
PSPhilippa Smith
Philippa Smith
AOAlex B. Olsen
Alex B. Olsen
CCCharles S Cox
Charles S Cox
We previously demonstrated that the intravenous delivery of multipotent adult progenitor cells (MAPCs) after traumatic brain injury (TBI) in rodents provides neuroprotection by preserving the blood-brain barrier and systemically attenuating inflammation in the acute time frame following cell treatment; however, the long-term behavioral and anti-inflammatory effects of MAPC administration after TBI have yet to be explored. We hypothesized that the intravenous injection of MAPCs after TBI attenuates the inflammatory response (as measured by microglial morphology) and improves performance at motor tasks and spatial learning (Morris water maze [MWM]). MAPCs were administered intravenously 2 and 24 hours after a cortical contusion injury (CCI). We tested four groups at 120 days after TBI: sham (uninjured), injured but not treated (CCI), and injured and treated with one of two concentrations of MAPCs, either 2 million cells per kilogram (CCI-2) or 10 million cells per kilogram (CCI-10). CCI-10 rats showed significant improvement in left hind limb deficit on the balance beam. On the fifth day of MWM trials, CCI-10 animals showed a significant decrease in both latency to platform and distance traveled compared with CCI. Probe trials revealed a significant decrease in proximity measure in CCI-10 compared with CCI, suggesting improved memory retrieval. Neuroinflammation was quantified by enumerating activated microglia in the ipsilateral hippocampus. We observed a significant decrease in the number of activated microglia in the dentate gyrus in CCI-10 compared with CCI. Our results demonstrate that intravenous MAPC treatment after TBI in a rodent model offers long-term improvements in spatial learning as well as attenuation of neuroinflammation.

1 November 2012 in Surgery
Verified
Journal Article
Closed access
PWPeter A. Walker
Peter A. Walker
SSShinil K. Shah
Shinil K. Shah
FJFernando Jimenez
Fernando Jimenez
KAKevin R. Aroom
Kevin R. Aroom
MHMatthew T. Harting
Matthew T. Harting
CCCharles S. Cox
Charles S. Cox

27 January 2010 in Tissue Engineering Part C: Methods
Verified
Journal Article
Closed access
PWPeter A. Walker
Peter A. Walker
FJFernando Jimenez
Fernando Jimenez
MGMichael H. Gerber
Michael H. Gerber
KAKevin R. Aroom
Kevin R. Aroom
SSShinil K. Shah
Shinil K. Shah
CCCharles S Cox
Charles S Cox
Introduction: Current mesenchymal stromal cell (MSC) delivery methods require infusion/implantation through needles and/or catheters. Little investigation into the effect of delivery via catheter injection has been completed. We hypothesize that injection of rat and human MSCs through various clinically relevant-sized catheters and flow rates will not affect cell viability, characterization, or function. Methods: Both rat and human MSCs were injected through 20-, 25-, and 30-gauge needles, as well through an SL-10 microcatheter at rates of 60, 120, 240, and 500 mL/h. MSC viability and apoptotic fraction was measured. MSCs were characterized 24 h after injection with flow cytometric immunophenotyping, and multilineage differentiation was completed. Results: Catheter diameter or flow rate did not affect rat MSC viability. No clinically significant decrease in human MSC viability was observed immediately after injection; however, a delayed decrease in viability was observed at 24 h. No difference in the surface markers CD11b, CD45, CD29, CD49e, CD73, CD90, CD105, and Stro-1 or the capacity for multilineage differentiation (adipogenesis, osteogenesis, and chondrogenesis) was observed for either rat or human MSCs. Conclusion: The injection of human and rat MSCs through various clinically relevant catheters and flow rates did not have a clinically significant effect on viability immediately after injection, indicating compliance with recently published Food and Drug Administration guidelines (viability >70%). Further, no changes in cell characterization or function were observed via measurement of cell surface markers and the capacity for multilineage differentiation, respectively. These results ensure the biocompatibility of MSCs with commonly used delivery methods.